Exelixis (NASDAQ:EXEL) stockholders approved all proposals presented at the company’s 2026 annual meeting, including the election of 11 directors, the ratification of Ernst & Young LLP as independent registered public accounting firm, an amendment to the company’s 2017 Equity Incentive Plan and an advisory vote on executive compensation.
President and CEO Michael Morrissey called the virtual meeting to order and said stockholders attending through the online portal were able to listen, submit questions and vote shares during the meeting. Exelixis executives present included Chris Senner, executive vice president and chief financial officer; Andrew Peters, senior vice president of strategy and investor relations; Brenda Hefti, senior vice president and general counsel, who served as secretary of the meeting; and Nina Iyer, vice president of corporate legal affairs and operations and board secretary, who served as inspector of election.
Quorum Established for Annual Meeting
Directors Elected to Serve Until 2027
Stockholders elected the 11 nominees put forward by the board of directors to serve until the next annual meeting of stockholders in 2027. Morrissey said no other nominations had been received or could be made at the meeting under the company’s bylaws.
The director nominees elected were Mary C. Beckerle, Ph.D.; [Asgal Ekart], M.D.; Maria C. Freire, Ph.D.; Tomas J. Heyman; David E. Johnson; Michael M. Morrissey, Ph.D.; Robert L. Oliver Jr.; Stelios Papadopoulos, Ph.D.; George Poste, DVM, Ph.D., FRS; Julie Anne Smith; and Jack L. Wyszomierski.
Auditor, Equity Plan and Compensation Votes Approved
Stockholders also ratified the selection of Ernst & Young LLP as Exelixis’ independent registered public accounting firm for the fiscal year ending Jan. 1, 2027. Representatives from Ernst & Young were present at the meeting and were available to answer questions concerning the company’s financial statements, Morrissey said.
In addition, stockholders approved the amendment and restatement of the Exelixis Inc. 2017 Equity Incentive Plan. Morrissey said the amendment included, among other items, an increase of 2 million shares authorized for issuance under the plan, as disclosed in the company’s proxy statement.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers as disclosed in the 2026 proxy statement.
No Stockholder Questions Addressed
After the preliminary voting results were announced, Morrissey moved to the question-and-answer portion of the meeting. He said the company had not received any stockholder questions or comments that were germane to the meeting and complied with the rules of conduct, so the Q&A session was not held.
Morrissey directed stockholders with later questions or feedback to contact Exelixis’ investor relations and public affairs team through the company’s website. The meeting was then concluded.
About Exelixis (NASDAQ:EXEL)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
